Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Clinical trial NCT03493685 · COMPLETED
Trial details
- NCT number
- NCT03493685
- Sponsor
- Travere Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-17
- Primary completion
- 2023-03-20
- Enrollment
- 371
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.